Back to search

Article

Engineering a pH-sensitive humanized infliximab with improved potency and developability using STEM™

2026-08-19

Abstract excerpt

<h4>Background</h4> Tumor necrosis factor-α inhibitors such as infliximab and adalimumab have transformed autoimmune disease treatment; however, infliximab is a mouse-human chimeric antibody that remains immunogenic, is associated with self-association/aggregation liability, and requires prolonged intravenous administration. We humanized infliximab and engineered infliximab-derived candidates with improved potenc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
55a15ca8-76cc-5ed2-a83a-b41803268536
DOI
10.64898/2026.08.18.745573
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Engineering a pH-sensitive humanized infliximab with improved potency and developability using STEM™DOI 10.64898/2026.08.18.745573
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseasesSemantic proximity
AI-assisted protein design to rapidly convert antibody sequences to intrabodies targeting diverse peptides and histone modificationsSemantic proximity
A resource of high-quality and versatile nanobodies for drug deliverySemantic proximity
Beyond antibodies: using biological principles to guide the development of next-generation protein therapeuticsSemantic proximity
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody librariesSemantic proximity
Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity
Stability engineering of the human antibody repertoireSemantic proximity
Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody DrugsSemantic proximity
AI-Guided Precision in Antibody Humanization: Structural Modeling to Minimize Immunogenicity and Preserve EfficacySemantic proximity
AI-Driven Design of Nanobinders Targeting the TSLPR Heterodimer Interface to Suppress Type 2 Inflammatory SignalingSemantic proximity
Data-driven evaluation of suitable immunogens for improved antibody selectionSemantic proximity
Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.Semantic proximity
Select a neighboring publication to make it the new centre.